Premenstrual Dysphoric Disorder Awareness and Research Act of 2026

Plain-English Summary: Premenstrual Dysphoric Disorder Awareness and Research Act of 2026

This bill focuses on Premenstrual Dysphoric Disorder (PMDD), a serious medical condition that affects some people who menstruate. PMDD is a severe form of premenstrual syndrome (PMS) that can cause significant emotional and physical symptoms — including intense mood changes, depression, and anxiety — in the days or weeks before a menstrual period. The bill appears aimed at increasing federal attention, funding, and resources directed toward understanding and addressing this condition.

Based on its title and legislative focus, the bill would likely direct federal agencies — such as the National Institutes of Health (NIH) or the Centers for Disease Control and Prevention (CDC) — to expand research into PMDD's causes, treatments, and prevalence. It may also include measures to improve public and medical awareness of the condition, which is often underdiagnosed or dismissed, meaning many people who suffer from it do not receive proper care or diagnosis.

This bill would most directly affect the estimated millions of Americans living with PMDD, as well as healthcare providers who treat them. Greater research funding could lead to better treatment options, while awareness efforts could help doctors recognize and diagnose the condition more quickly. Indirectly, it could influence how insurance companies and the medical community classify and respond to PMDD.

The bill has been introduced in the House of Representatives and referred to the House Committee on Energy and Commerce, which oversees health-related legislation. It is in the very early stages of the legislative process, and no official description has been provided, so some details about its specific provisions remain unclear until the full bill text is available.